UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of April 2022
Commission File Number: 001-40106
4D pharma plc
(Translation of Registrant’s name into English)
5th Floor, 9 Bond Court
Leeds
LS1 2JZ
United Kingdom
Tel: +44 (0) 113 895 013
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
4D pharma Reports Full Year 2021 Financial Results, Operational Highlights, and Guidance for Key Milestones in 2022
On April 1, 2022, 4D pharma plc (the “Company”) issued a press release to announce that the Annual Report for the year ended December 31, 2021 (the “Annual Report”) has been reported and that its key corporate objectives for 2022 have been highlighted.
A copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein. The information in Exhibit 99.1 relates to the Company’s IFRS results, US GAAP details can be found in the Company’s form 20-F filed with the SEC.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
4D pharma plc | |
Date: April 4, 2022 | /s/ Duncan Peyton |
Duncan Peyton | |
Chief Executive Officer |
INDEX TO EXHIBITS
Exhibit | ||
Number | Exhibit Title | |
99.1 | Press Release, dated April 1, 2022. |